Loading...

Moolec Science S.A.

MLECNASDAQ
Healthcare
Biotechnology
$7.01
$-0.26(-3.58%)
U.S. Market is Open • 14:16

Moolec Science S.A. Fundamental Analysis

Moolec Science S.A. (MLEC) shows weak financial fundamentals with a PE ratio of -0.03, profit margin of -33.41%, and ROE of 3.77%. The company generates $0.6B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position286.85%
PEG Ratio0.01

Areas of Concern

ROE3.77%
Operating Margin-3.14%
Current Ratio0.13
We analyze MLEC's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -85.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-85.0/100

We analyze MLEC's fundamental strength across five key dimensions:

Efficiency Score

Weak

MLEC struggles to generate sufficient returns from assets.

ROA > 10%
-54.45%

Valuation Score

Excellent

MLEC trades at attractive valuation levels.

PE < 25
-0.03
PEG Ratio < 2
0.01

Growth Score

Weak

MLEC faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

MLEC shows balanced financial health with some risks.

Debt/Equity < 1
-3.74
Current Ratio > 1
0.13

Profitability Score

Weak

MLEC struggles to sustain strong margins.

ROE > 15%
3.77%
Net Margin ≥ 15%
-33.41%
Positive Free Cash Flow
No

Key Financial Metrics

Is MLEC Expensive or Cheap?

P/E Ratio

MLEC trades at -0.03 times earnings. This suggests potential undervaluation.

-0.03

PEG Ratio

When adjusting for growth, MLEC's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values Moolec Science S.A. at -0.05 times its book value. This may indicate undervaluation.

-0.05

EV/EBITDA

Enterprise value stands at 3.49 times EBITDA. This is generally considered low.

3.49

How Well Does MLEC Make Money?

Net Profit Margin

For every $100 in sales, Moolec Science S.A. keeps $-33.41 as profit after all expenses.

-33.41%

Operating Margin

Core operations generate -3.14 in profit for every $100 in revenue, before interest and taxes.

-3.14%

ROE

Management delivers $3.77 in profit for every $100 of shareholder equity.

3.77%

ROA

Moolec Science S.A. generates $-54.45 in profit for every $100 in assets, demonstrating efficient asset deployment.

-54.45%

Following the Money - Real Cash Generation

Operating Cash Flow

Moolec Science S.A. generates limited operating cash flow of $-41.21M, signaling weaker underlying cash strength.

$-41.21M

Free Cash Flow

Moolec Science S.A. generates weak or negative free cash flow of $-50.73M, restricting financial flexibility.

$-50.73M

FCF Per Share

Each share generates $-69.87 in free cash annually.

$-69.87

FCF Yield

MLEC converts -5.73% of its market value into free cash.

-5.73%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.03

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.006

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.05

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.02

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-3.74

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.13

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

3.77

vs 25 benchmark

ROA

Return on assets percentage

-0.54

vs 25 benchmark

ROCE

Return on capital employed

0.33

vs 25 benchmark

How MLEC Stacks Against Its Sector Peers

MetricMLEC ValueSector AveragePerformance
P/E Ratio-0.0329.43 Better (Cheaper)
ROE376.84%692.00% Weak
Net Margin-33.41%-44295.00% (disorted) Weak
Debt/Equity-3.740.35 Strong (Low Leverage)
Current Ratio0.134.48 Weak Liquidity
ROA-54.45%-18045.00% (disorted) Weak

MLEC outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Moolec Science S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ